Back to discover

Protein / target

T-box transcription factor TBX21

Encoded byTBX21Q9UL17Homo sapiensSwiss-Prot
Degrader-tractable
Druggability
UniProt Ubiquitination
1
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Hypothyroidism

Via encoding gene TBX21 · Genetic evidence · score 0.91

Research activity

Emerging research

1 papers · latest 2015

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Lineage-defining transcription factor which initiates Th1 lineage development from naive Th precursor cells both by activating Th1 genetic programs and by repressing the opposing Th2 and Th17 genetic programs.

View complete UniProt function annotation

Lineage-defining transcription factor which initiates Th1 lineage development from naive Th precursor cells both by activating Th1 genetic programs and by repressing the opposing Th2 and Th17 genetic programs (PubMed:10761931). Activates transcription of a set of genes important for Th1 cell function, including those encoding IFN-gamma and the chemokine receptor CXCR3. Induces permissive chromatin accessibility and CpG methylation in IFNG (PubMed:33296702). Activates IFNG and CXCR3 genes in part by recruiting chromatin remodeling complexes including KDM6B, a SMARCA4-containing SWI/SNF-complex, and an H3K4me2-methyltransferase complex to their promoters and all of these complexes serve to establish a more permissive chromatin state conducive with transcriptional activation (By similarity). Can activate Th1 genes also via recruitment of Mediator complex and P-TEFb (composed of CDK9 and CCNT1/cyclin-T1) in the form of the super elongation complex (SEC) to super-enhancers and associated genes in activated Th1 cells (PubMed:27292648). Inhibits the Th17 cell lineage commitment by blocking RUNX1-mediated transactivation of Th17 cell-specific transcriptinal regulator RORC. Inhibits the Th2 cell lineage commitment by suppressing the production of Th2 cytokines, such as IL-4, IL-5, and IL- 13, via repression of transcriptional regulators GATA3 and NFATC2. Protects Th1 cells from amplifying aberrant type-I IFN response in an IFN-gamma abundant microenvironment by acting as a repressor of type-I IFN transcription factors and type-I IFN-stimulated genes. Acts as a regulator of antiviral B-cell responses; controls chronic viral infection by promoting the antiviral antibody IgG2a isotype switching and via regulation of a broad antiviral gene expression program (By similarity). Required for the correct development of natural killer (NK) and mucosal-associated invariant T (MAIT) cells (PubMed:33296702)

Subcellular location

Nucleus
Domains and Gene Ontology detail (30)

Gene Ontology

  • Cchromatin
  • Ccytoplasm
  • Cneuronal cell body
  • Cnucleus
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FDNA-binding transcription repressor activity, RNA polymerase II-specific
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fsequence-specific DNA binding
  • Fsequence-specific double-stranded DNA binding
  • Ftranscription cis-regulatory region binding
  • Pcell fate specification

535 aa · 58 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Immune signalling

  • ·Lineage-defining transcription factor which initiates Th1 lineage development from naive…
  • ·leukocyte migration involved in inflammatory response
  • ·negative regulation of interleukin-2 production
  • ·negative regulation of T-helper 2 cell cytokine production

Transcriptional regulation

  • ·Lineage-defining transcription factor which initiates Th1 lineage development from naive…
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific
  • ·DNA-binding transcription repressor activity, RNA polymerase II-specific

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TBX21

Gene-level evidence surfaced through the gene TBX21that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypothyroidism
0.91Well supported

Genetic evidence dominant · Open Targets 0.55

Thyroid Diseases
0.86Well supported

Genetic evidence dominant · Open Targets 0.52

Asthma
0.68Moderately supported

Genetic evidence dominant · Open Targets 0.39

Childhood onset asthma
0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Lower respiratory tract disorder
0.59Moderately supported

Genetic evidence dominant · Open Targets 0.36

View evidence synthesis (5)
HypothyroidismWell supported
0.91
agreement 0.791.00
Genetic100%

Open Targets aggregate 0.55 · 1 independent evidence family

Thyroid DiseasesWell supported
0.86
agreement 0.740.98
Genetic100%

Open Targets aggregate 0.52 · 1 independent evidence family

AsthmaModerately supported
0.68
agreement 0.560.80
Genetic79%Animal model14%Literature7%

Open Targets aggregate 0.39 · 3 independent evidence families

Childhood onset asthmaModerately supported
0.63
agreement 0.490.77
Genetic99%Literature1%

Open Targets aggregate 0.38 · 2 independent evidence families

Lower respiratory tract disorderModerately supported
0.59
agreement 0.470.71
Genetic100%

Open Targets aggregate 0.36 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypothyroidism0.55
Thyroid Diseases0.52
Neurodegenerative Diseases0.52
Asthma0.39
Childhood onset asthma0.38
Lower respiratory tract disorder0.36
Hashimoto's Disease0.36
Autoimmune Diseases0.35

Tractability

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)
PR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2015

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Jiang Y · Cell death & disease · 2015

Recent

T-cell exhaustion in the tumor microenvironment.

Jiang Y · Cell death & disease · 2015

Europe PMC papers linked directly to this protein.